Dual-Peptide Delivery System Penetrates Deep Into Tumors to Deliver Cancer-Killing Drugs
A liposome system combining tumor-penetrating peptide NGR and cell-penetrating peptide R9 delivered doxorubicin deep into tumors by overcoming multiple biological barriers.
Quick Facts
What This Study Found
Liposomes coated with both tumor-penetrating (cyclic iNGR) and cell-penetrating (R9) peptides achieved synergistic penetration of multiple biological barriers, delivering doxorubicin deep into tumor tissue and cells in vitro and in vivo.
Key Numbers
The modified NGR peptide demonstrated enhanced multi-barrier penetration compared to the original iNGR tumor-penetrating peptide.
How They Did This
Developed Lip-mbPDS liposomes coated with R9 CPP and cyclic iNGR peptide. Tested in CD13-positive HT1080 fibrosarcoma cells using confocal microscopy, cell internalization/toxicity assays, 3D tumor spheroid penetration, and in vivo antitumor efficacy in mouse models.
Why This Research Matters
Many cancer drugs are effective at killing cancer cells in a dish but fail in patients because they cannot penetrate solid tumors deeply enough. This dual-peptide approach solves multiple penetration barriers simultaneously, potentially making existing drugs more effective.
The Bigger Picture
The tumor penetration problem is one of the biggest unsolved challenges in cancer drug delivery. By combining peptides that solve different barriers — one for getting into the tumor and another for getting into cells — this synergistic approach demonstrates a general strategy that could improve the delivery of many existing cancer drugs.
What This Study Doesn't Tell Us
Preclinical study using a single tumor model (HT1080 fibrosarcoma). Different tumor types may present different penetration challenges. Liposome stability and manufacturing scalability not addressed. Clinical translation requires extensive safety and efficacy testing in humans.
Questions This Raises
- ?Does this dual-peptide system improve outcomes across different solid tumor types, especially dense tumors like pancreatic cancer?
- ?Can the system be loaded with drugs other than doxorubicin, including newer immunotherapy agents?
- ?What is the safety profile of this multi-peptide system in normal tissues?
Trust & Context
- Key Stat:
- Multi-barrier penetration Combining tumor-targeting and cell-penetrating peptides achieved synergistic deep tumor drug delivery that neither peptide accomplished alone
- Evidence Grade:
- Preliminary evidence: proof-of-concept preclinical study with promising in vitro and in vivo results in a single tumor model. Far from clinical application.
- Study Age:
- Published in 2024. Represents current advances in peptide-based tumor-penetrating drug delivery.
- Original Title:
- Multibarrier-penetrating drug delivery systems for deep tumor therapy based on synergistic penetration strategy.
- Published In:
- Biomaterials science, 12(9), 2321-2330 (2024)
- Authors:
- Zhang, Hui-Feng, Yu, Huan(4), Pan, Shuang-Xue, Zhang, Chuang, Ma, Ying-Hui, Zhang, Yan-Fei, Zuo, Li-Li, Hao, Cheng-Yi, Lin, Xiao-Ying, Geng, Hao, Wu, Di, Mu, Shang-Qiang, Yu, Wei-Lun, Shi, Nian-Qiu
- Database ID:
- RPEP-09637
Evidence Hierarchy
Frequently Asked Questions
Why can't regular cancer drugs reach tumors?
Solid tumors have multiple barriers: dense tissue, high pressure, irregular blood vessels, and tough cell membranes. Most drugs get stuck at the tumor edge. This dual-peptide system uses one peptide to navigate into tumor tissue and another to cross cell membranes.
What are tumor-penetrating peptides?
Tumor-penetrating peptides (TPPs) are short amino acid chains that can guide drug carriers deep into tumor tissue. They work by binding to receptors on tumor cells and activating pathways that transport them through biological barriers that normally block drug entry.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09637APA
Zhang, Hui-Feng; Yu, Huan; Pan, Shuang-Xue; Zhang, Chuang; Ma, Ying-Hui; Zhang, Yan-Fei; Zuo, Li-Li; Hao, Cheng-Yi; Lin, Xiao-Ying; Geng, Hao; Wu, Di; Mu, Shang-Qiang; Yu, Wei-Lun; Shi, Nian-Qiu. (2024). Multibarrier-penetrating drug delivery systems for deep tumor therapy based on synergistic penetration strategy.. Biomaterials science, 12(9), 2321-2330. https://doi.org/10.1039/d3bm01959d
MLA
Zhang, Hui-Feng, et al. "Multibarrier-penetrating drug delivery systems for deep tumor therapy based on synergistic penetration strategy.." Biomaterials science, 2024. https://doi.org/10.1039/d3bm01959d
RethinkPeptides
RethinkPeptides Research Database. "Multibarrier-penetrating drug delivery systems for deep tumo..." RPEP-09637. Retrieved from https://rethinkpeptides.com/research/zhang-2024-multibarrierpenetrating-drug-delivery-systems
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.